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Meta-analysis of the influence 
of TM6SF2 E167K variant 
on Plasma Concentration of 
Aminotransferases across different 
Populations and Diverse Liver 
Phenotypes
Silvia Sookoian1 & Carlos J. Pirola2
A nonsynonymous E167K (rs58542926 C/T) variant in TM6SF2 gene was recently associated with 
nonalcoholic fatty liver disease (NAFLD). We explored the association between E167K and plasma 
concentrations of alanine (ALT) and aspartate (AST) aminotransferases through a meta-analysis. We 
also estimated the strength of the effect across diverse liver phenotypes, including NAFLD and chronic 
viral hepatitis; fourteen studies were included. We found that ALT (p = 3.2 × 10−6, n = 94,414) and AST 
(p = 0007, n = 93,809) levels were significantly associated with rs58542926 in NAFLD. By contrast, 
rs58542926 was not associated with either ALT (p = 0.24, n = 4187) or AST (p = 0.17, n = 2678) levels 
in four studies on chronic hepatitis. In conclusion, the results of the pooled estimates in patients with 
NAFLD showed that carriers of the T allele (EK + KK), when compared with homozygous subjects for 
the C allele (EE genotype) have increased levels of aminotransferases; however, this increase represents 
–2.5 (9.8%) and 1.2 (5%) IU/L of ALT and AST respectively, which is fairly small compared with the large 
effect of PNPLA3- rs738409-G allele that is associated with a –28% increase in serum ALT.
Plasma concentrations of alanine (ALT) and aspartate (AST) aminotransferases have been classically regarded 
as markers of liver injury, including a wide range of etiologies from viral hepatitis to nonalcoholic fatty liver 
(NAFLD)1. Indeed, under the assumptions that liver cell membrane damage is associated with the subsequent 
leakage of intracellular enzymes into the circulation, in addition to the fact that aminotransferases are highly 
expressed in hepatocytes, the measurement of circulating ALT and AST enzymatic activity is commonly used 
in clinical practice to evaluate and monitor the course of any acute or chronic liver disease associated with liver 
damage.
The large body of evidence derived from epidemiological studies on the prevalence of obesity, type 2 diabetes 
(T2D), and cardiovascular disease (CVD) has uncovered an unexpected but biologically plausible association 
between aminotransferases and all of the individual components of the metabolic syndrome (MetS), as recently 
reviewed2. The findings obtained by the Framingham Offspring Heart Study showed that ALT levels are not only 
highly correlated with incident MetS, but are also significantly associated with the increased risk of T2D and 
incident CVD over a 20-year follow-up period3. Recent results from a patient-oriented-research study from our 
group showed that in the context of abnormal hepatic triglyceride accumulation, circulating aminotransferases 
rise putatively as a consequence of the increased tissular reactions of transamination in order to cope with the 
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liver metabolic derangement4. Hence, the ALT and AST levels might be regarded as sensors of global metabolic 
deregulation, including mitochondrial energetic control4.
Like all circulating substances, the plasma levels of aminotransferases are highly variable and are affected by a 
myriad of factors including genetic predisposition5,6; for instance, the estimated heritability of ALT is about 33%7. 
The first genome-wide association study (GWAS) of plasma liver-enzyme levels identified two loci influencing 
ALT levels, one of which included two imputed-nonsynonymous SNPs within patatin-like phospholipase domain 
containing 3 (PNPLA3) (rs738409 Ile148Met, p = 3.7 × 10−10 and rs2294918 Lys434Glu, p = 6.0 × 10−4)8. This 
finding was further replicated in a subsequent larger GWAS (n = 61,089 individuals) demonstrating a remarkably 
similar effect for the rs738409 (p value for the association of ALT 1.2 × 10−45)9. Likewise, the results of the first 
GWAS on NAFLD also found an association between the rs738409 and serum ALT levels, although this associa-
tion was only restricted to the Hispanic group, which was the ethnic group with the greatest prevalence of hepatic 
steatosis in the recruited population10. Summarized evidence from the following-up candidate-gene association 
studies demonstrated that carriage of the homozygous state for the rs738409-G allele is associated with a ~28% 
increase in serum ALT levels11.
A recent exome-wide association study of liver fat content showed that rs58542926 (E167K), a nonsynony-
mous variant located in TM6SF2 (Transmembrane 6 Superfamily Member 2), was also associated with modest p 
values for the association with ALT but not AST in the Dallas Heart Study and The Dallas Biobank12, while it also 
bore a large significance, at least for ALT (p = 7.6 × 10−14) in the Copenhagen Study12. A concomitant GWAS on 
genes influencing lipid traits also found the rs58542926 associated with total cholesterol levels and myocardial 
infarction risk13. Successive explorations of the association between E167K and NAFLD showed that this variant 
has a modest effect on liver fat accumulation, and also a dual and opposite role in protecting against CVD and 
conferring risk for NAFLD14.
Furthermore, conflicting and non-replicated results found in some15–17 but not all of the studies18 that the 
E167K variant could be associated with steatosis in patients with the hepatitis C virus (HCV) as well; nevertheless, 
the associations with liver enzymes could not be demonstrated in patients with chronic hepatitis.
Interestingly, the results from the two above-mentioned GWAS on liver enzymes8,9 do not appear to suggest 
any significant association between E167K or any other variant in the linkage disequilibrium in the TM6SF2 
locus- and aminotransferases. Hence, whether the rs58542926 has any effect on the circulating levels of ALT 
or AST is still unknown. As the literature shows conflicting and inconclusive results, our primary purpose was 
to explore the putative association between the rs58542926 variant and plasma levels of aminotransferases by a 
meta-analysis of existing data. In addition, we estimated the strength of the effect of rs58542926 on both circulat-
ing ALT and AST across different populations and diverse liver phenotypes, including NAFLD and chronic viral 
hepatitis.
Results
We evaluated fourteen studies that were identified using the search strategy described in Supplementary Fig. 1. 
Characteristics of studies included in the meta-analysis of liver enzymes in NAFLD12,16,19–27 (n = 11) are shown 
in Table 1, while those included in the meta-analysis of patients with viral hepatitis15–18 (n = 4) are summarized 
in Table 2.
Basic details of the included studies, including location, main clinical descriptors and sample size, and also 
major concerns or putative bias of the studies are summarized in Tables 1 and 2. In addition, Tables 1 and 2 
include information on quality and methodology of the included studies, specifically, putative selection bias of 
the study design and setting, which is required in the HuGENet guidelines. Selection criteria, reference test, blind 
assessment of the reference test, and the availability of clinical data were disclosed in the majority of the studies.
Study Characteristics. Eleven studies included in the meta-analysis were hospital-based15–24,27, while the 
other three were population-based12,25,26 studies; three studies included pediatric population20,21,25.
Genotyping for rs58542926 was carried out using a Taqman assay15,17–19,21–24,26,27, Sequenom MassARRAY 
system and iPLEX Gold chemistry16, automated sequencing20, Exome BeadChip25, and specific Illumina arrays 
(Illumina, CA, USA)12.
Concordance with Hardy-Weinberg equilibrium (HWE) was observed in all the studies as stated by the 
authors; specific assessment of departure from HWE was further performed according to the genotype frequen-
cies reported in any paper whenever this information was not disclosed.
The influence of TM6SF2 E167K variant on plasma concentration of aminotransferases in 
subjects with NAFLD. Associations for the plasma levels of ALT were extracted from eleven studies12,16,19–27, 
while the associations for plasma levels of AST were extracted from nine studies12,16,19–21,23,24,26,27. The mean values 
of ALT and AST, according to the genotypes of the dominant model of rs58542926 in each study are disclosed in 
Table 1.
We found that the plasma concentration of ALT was significantly associated with rs58542926 variant (random 
model p = 3.2 × 10−6) (Fig. 1) without evidence of publication bias (p = 0.44) in a sample of 94,414 individuals of 
both genders. The analysis revealed a significant heterogeneity (p = 0.0032, I2: 58.1) that by the sensitivity analysis 
it was primarily attributed to the studies including pediatric population20,21,25. Results on the ALT levels stratified 
by age are shown in Supplementary Fig. 2; heterogeneity disappeared when studies that included children were 
grouped apart in the analysis (p = 0.45, I2: 0).
Likewise, circulating AST levels were significantly associated with rs58542926 variant (random model 
p = 0.00079, n = 93,809) (Fig. 2) without any evidence of publication bias (p = 0.33) but with evidence of het-
erogeneity (p = 0.004, I2: 57.3) that was also successfully solved when the studies that included pediatric 
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Study ref. and Population Ethnicity 
(Country)




Comments on potential 
concerns and bias
ALT mean ± SD AST mean ± SD




Patients with NAFLD 
diagnosed by liver biopsy. 
Age: 42 ± 6 Female %: 48 
TaqMan assay. 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 
untested by the authors. 
A control group is 
not available; patients 
with NAFLD might be 
recruited due to- but not 
restricted to- abnormal 
aminotransferase levels.
44.0 ± 34.1 46.0 ± 32.6 30.0 ± 17.0 30.0 ± 16.3
Dongiovanni, 2015, b19 
European descendent 
(Finland and Sweden)
SOS Study: Morbid obese 
subjects enrolled for 
bariatric surgery. Age: 
49 ± 7 Female %: 70
TaqMan assay. 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 
untested by the authors. 46.0 ± 20.7 51.0 ± 28.2 35.0 ± 11.9 37.0 ± 14.8
2 Eslam, 2016, a
16 (European 
Population)
Patients with NAFLD 
diagnosed by liver biopsy. 




system, iPLEX Gold 
chemistry. Genotypes 
were tested and found 
to be in HWE.
Population stratification 
untested by the authors. 
A control group is 
not available, patients 
with NAFLD might be 
recruited due to- but not 
restricted to- abnormal 
aminotransferase levels.




Obese children > 95th 
percentile recruited to 
explore the association 
between lipid traits and 
hepatic steatosis. Age: 
10.5 ± 2.9. Female %: 50
TaqMan assay. 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 
untested by the authors. 
A control group is not 
available; data is only on 
obese patients.
28.0 ± 16.1 34.0 ± 18.6 24.2 ± 9.4 25.7 ± 10.5
4
Goffredo, 2016, a20 
Caucasians (USA)
Obese children and 
adolescents recruited 
from the Yale Pediatric 
Obesity Clinic. Age: 
13 ± 3.5 Female %: 60
Automated 
sequencing. 
Genotypes were tested 
and filtered to be in 
HWE.
Population stratification 
untested by the authors. 
A control group is not 
available, and data is 
only on obese patients.
26.3 ±  24.1 36.0 ±  59.0 24.0 ±  11.6 29.4 ±  36.0
Goffredo, 2016, b20 African 
Americans (USA)




Genotypes were tested 
and filtered to be in 
HWE.
Population stratification 
untested by the authors. 
A control group is not 
available, and data is 
only on obese patients.
16.9 ±  8.6 14.2 ±  5.7 21.4 ±  6.3 20.8 ±  5.7
Goffredo, 2016, c20 
Hispanics (USA) Age: 13 ± 3 Female %: 50
Automated 
sequencing. 
Genotypes were tested 
and filtered to be in 
HWE.
Population stratification 
untested by the authors. 
A control group is not 
available, and data is 
only on obese patients.
26.4 ±  21.5 47 ±  60 24.7 ±  9.3 38.5 ±  42
5




Dallas Heart Study: 
individuals recruited for 
exploration of CV risk 
factors and fatty liver. 





were tested and 
filtered to be in HWE.
Population stratification 
was computed by 
ancestry markers.
23.5 ± 19.9 25.9 ± 18.3 24.3 ± 20.6 25.1 ± 19.5
Kozlitina, 2014, b12 
European-Americans (USA)
Preventive medicine, 
Dallas Biobank Texas 
Age:53± 11 Female %:35
Taqman assay. 
Genotypes were tested 






35.9 ± 16.3 36.9 ± 15.5 27.0 ± 13.8 27.1 ± 10.9
Kozlitina, 2014, c12 12 
Danish population (Sweden)
Copenhagen General 
Population Study and 
the Copenhagen City 
Heart Study. Age: 58 ± 10 
Female %: 55
Taqman assay 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 
unlikely: all participants 
were of Danish descent.





to assess dietary 
intervention Age: 48 
(18–74) Female %: 38
Taqman assay 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 




Patients recruited in a 
controlled trial on the 
effect of 4 g per day of a 
omega-3 fatty acid. Age: 
50 ± 9.6 Female %: 17
TaqMan assay. 
HWE not tested; 
calculations cannot 
be done because 
the authors did not 
disclose full genotypes 
counts.
Population stratification 
untested by the authors. 55.0 ± 51.0 55.0 ± 58.0 42.0 ± 24.0 39.0± 40.0
8




patients with NAFLD 
diagnosed by liver biopsy. 
Age: 50 ± 12 Female 
%: 62
TaqMan assay. 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 




Subjects assessed for 
non-invasive screening 
of fatty liver and liver 
fibrosis. Age: 46 ± 10 
Female %: 58
TaqMan assay. 
Authors did not 
report HWE testing, 
but our calculations 
show that all genotype 
frequencies were in 
HWE 
Population stratification 
untested but unlikely 
as the subjects were 
restricted to Chinese.
21.0 ± 10.4 22.2 ± 9.1 19.0 ± 4.44 20.1 ± 8.2
Continued
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population20,21 were grouped apart in the analysis (p = 0.12, I2: 36.9); the results on AST levels stratified by age are 
shown in Supplementary Fig. 3.
The influence of TM6SF2 E167K variant on plasma concentration of aminotransferases in 
subjects with viral hepatitis. The analysis included a total of 4187 subjects from which the values of ALT 
according to E167K genotypes could be extracted15–18; this sample included 3680 patients with HCV and 507 
patients with HBV. Only two studies reported data on AST levels15,16. The mean value of ALT and AST according 
to genotypes of the dominant model of rs58542926 in each study is disclosed in Table 2.
Of note, the rs58542926 variant was not associated with ALT levels either in the fixed or random (p = 0.245) 
models (Fig. 3A) in the total sample of 4187 individuals without evidence of heterogeneity (p = 0.94, I2: 0) or pub-
lication bias (p = 0.22). Neither was the rs58542926 variant associated with plasma AST levels (fixed or random 
model p = 0.172) in a smaller sample that included 2678 individuals without evidence of heterogeneity (p = 0.94, 
I2: 0) or publication bias (p = 0.296) (Fig. 3B).
Discussion
We explored the influence of rs58542926, a missense variant of TM6SF2, which is involved in the regulation of 
lipid metabolic process, on the concentration of aminotransferases in the circulating compartment. Interestingly, 
by means of a comprehensive and free from bias meta-analysis of the published evidence, we found that the 
rs58542926 variant exerts a moderate but statistically significant effect on the circulating levels of both ALT and 
AST in patients with NAFLD, but not in chronic viral hepatitis.
Limitations and quality of the evidence. The results of this meta-analysis show no evidence of publica-
tion bias; assessment of completeness of information, validity of individual studies, and analytic value of the test 
investigated suggest that the overall quality and methodology of studies was high. Nevertheless, some potential 
limitations deserve to be discussed. First, the presence of heterogeneity may potentially restrict the interpretation 
of the pooled risk estimates, particularly concerning the association of the variant with ALT and AST in NAFLD. 
However, the random effect model that does not depend on heterogeneity yielded a significant result pertaining 
to the association with both enzymes. More importantly, after performing a sensitivity analysis in the complete 
dataset, we observed that the heterogeneity was explained by three studies that enrolled pediatric population3,20,25. 
One potential explanation could be given by the fact that a large proportion of children and adolescents included 
in the above-mentioned studies were eligible for inclusion if they were obese or had any metabolic perturbation, 
including insulin resistance. Thereby, selection bias could explain why studies that involved pediatric population 
have introduced heterogeneity into the main joined analysis. On the other hand, the fact that pediatric-NAFLD 
differs from adult-NAFLD not only in the histological picture but also in the natural history of the disease28 might 
also explain the observed heterogeneity.
Second, raw data of each study was not fully available; that explain why the results (rs58542926-effects) pre-
sented in our meta-analysis slightly differ from those in the original studies. In fact, we had to convert some 
values of medians and interquartile range or range into mean and SD in some of the studies. Third, we could not 
provide an estimation of the effect of the variant in the additive model because of the low frequency of the T-allele 
(167 K); thus, all the calculations were based on the dominant model of inheritance. Four, there were differences 
in the study-design between the two main liver phenotypes; while studies of patients with NAFLD were either 
population or hospital-based studies that included either control subjects, cases and controls, or cases only; stud-
ies of patients with chronic hepatitis were exclusively disease-centric studies that included only cases. Five, we 
were not able to assess the effect of the variant on the plasma levels of aminotransferases according to sex, because 
the studies did not disclose data of ALT or AST values separately in men and women. Finally, a limitation that is 
an intrinsic defect of the cross-sectional design of all the included studies, and which cannot be solved by any spe-
cific analysis, is that the values of liver enzymes incorporated into our meta-analysis correspond to the circulating 
measurement of aminotransferases at only one point in time. Hence, biological oscillations of transaminases, even 
the ones experimented during the day, after a meal, or exercise29, and more importantly, oscillations explained by 
Study ref. and Population Ethnicity 
(Country)




Comments on potential 
concerns and bias
ALT mean ± SD AST mean ± SD




Subjects recruited for 
performing metabolic 
studies; target population 
obese and T2D patients. 




Genotypes were tested 
and found to be in 
HWE.
Population stratification 






to assess physical activity 
and diet intervention 
study Age: 7.6 ± 0.4 
Female %: 49
Exome BeadChip 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 
untested by the authors. 21.0 ± 8.5 18.3 ± 5.8 ND ND
Table 1. The association between the nonsynonymous rs58542926 variant of TM6SF2 and aminotransferase 
(ALT and AST) levels in studies of patients with nonalcoholic fatty liver disease (NAFLD): Characteristics 
of the studies and potential bias. HWE: Hardy-Weinberg equilibrium. Age expressed in years, mean ± standard 
deviation or mean (range) as stated in the referenced manuscripts. CV: cardiovascular. ND: Not done.
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potential changes in the disease behavior, such as flare-ups during the course of chronic hepatitis, could all affect 
the overall effect, although in a large dataset this noise may be compensated.
Implications for the understanding of the role of aminotransferases in liver disease. The signif-
icant association of rs58542926 and circulating levels of aminotransferases in patients with NAFLD was observed 
after collecting data from a large dataset consisting of 94,414 individuals for ALT and 93,809 individuals for AST. 
More specifically, the results of the pooled estimates showed that carriers of the minor T allele (EK + KK indi-
viduals) compared with homozygous subjects for the ancestral C allele (EE genotype) have higher levels of liver 
enzymes. However, it is difficult to attribute a meaningful clinical value to this finding that represents approxi-
mately an increase of ~2.5 (9.8%) IU/L of ALT and 1.2 (5%) IU/L of AST, or at least, this finding lacks of a satis-
factory clinical interpretation at the population level. For instance, as mentioned earlier, compared with the large 
effect of the PNPLA3 rs738409-G allele that is associated with a 28% increase in serum ALT levels11, it is hard 
to attribute the TM6SF2 locus a direct role in the modulation of circulating levels of transaminases as surrogate 
indicators of liver damage and/or inflammation. This assumption is partially supported by the divergent results 
of the association of rs58542926 and aminotransferases in NAFLD vs. chronic hepatitis. Notably, compared with 
NAFLD, though in a smaller but adequate statistical power- sample encompassing 4187 patients with chronic 
viral hepatitis, the rs58542926 had no effect on the circulating levels of ALT and AST.
What could be the reasons for this apparent discrepancy between the effect of the E167K variant in NAFLD 
and chronic viral hepatitis?
In patients with chronic hepatitis, rather than liver steatosis, liver damage, inflammation, and necrosis are part 
of the main histological picture; then, plasma levels of aminotransferases probably reflect liver injury more accu-
rately than metabolic perturbations. An interesting aspect to highlight that reinforces the previous assumption 
is the significant difference (p = 0.0001) between the mean ALT value in the studies of patients with NAFLD 
(25.3 ± 19.5 IU/L) compared that of the studies of patients with chronic hepatitis (72.49 ± 167.82 IU/L). 
Similarly, the plasma levels of AST significantly (p = 0.0001) differ between the studies of patients with NAFLD 
(23.96 ± 15.3 IU/L) versus studies of patients with chronic hepatitis (51.98 ± 124.91 IU/L). These differences prob-
ably reflect a distinctive clinical meaning of the elevated levels of these enzymes in each of the two phenotypes. 
For instance, in patients with chronic viral hepatitis, the elevation of aminotransferases in the order of ~ two 
times or more the upper normal limit most likely represents histological changes associated with hepatocel-
lular injury. On the contrary, circulating ALT or AST values in NAFLD, which are hardly ever in the range of 
chronic hepatitis and can be even in the “normal” range, do not necessarily represent histological severity but 
rather metabolic perturbations4,30,31. Several observations support the notion that aminotransferases are not only 
induced in NAFLD4,32, but that the liver gene expression of transaminase isoforms correlates with the ALT and 
AST levels in the circulating compartment, along with metabolites of the Krebs cycle4. For instance, long-term 
follow-up results from the Framingham Offspring Heart Study suggest that aminotransferases are associated 
with the long-term development of multiple metabolic disorders3. In addition, results from large epidemiological 
Study ref. and Population 
Ethnicity (Country)




Comments on potential 
concerns and bias
ALT mean ± SD AST mean ± SD





HCV Age: 44.8 ± 10.7 
Female %: 37.7 
Sequenom 
MassARRAY system 
and iPLEX Gold 
chemistry. Genotypes 
were tested and found 
to be in HWE.
Population stratification 








and iPLEX Gold 
chemistry. Genotypes 
were tested and found 
to be in HWE.
Population stratification 






HCV Age 52 ± 12.9 
Female %: 45
TaqMan assay. 
HWE not tested; 
calculations cannot 
be done because 
the authors did not 
disclose full genotypes 
counts.
Population stratification 
untested by the authors. 79.0 ± 61.0 88.6 ± 70.0 52.0 ± 35.0 57.0 ± 34.0
3




HCV Age: 53 ± 11 
Female %: 40
TaqMan assay. 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 






HCV Age: 57.5 ± 13 
Female %: 39.5
TaqMan assay. 
Genotypes were tested 
and found to be in 
HWE.
Population stratification 
untested by the authors. 51.0 ± 49.6 47.0 ± 43.7 ND ND
Table 2. The association between the nonsynonymous rs58542926 variant of TM6SF2 and 
aminotransferase (ALT and AST) levels in studies of patients with chronic viral hepatitis C (HCV) or B 
(HBV): Characteristics of the studies and potential bias. HWE: Hardy-Weinberg equilibrium. ND: not done. 
Age expressed in years, mean ± standard deviation or mean (range) as stated in the referenced manuscripts.
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studies worldwide, such as the National Health and Nutrition Examination Survey (NHANES) have consistently 
demonstrated that elevations of aminotransferases in the general population are associated with risk factors for 
NAFLD, including central adiposity and hyperinsulinemia33,34. Similar studies from Asia (National Health and 
Nutrition Examination Survey K-NHANES) replicated these results not only in the adult population35, but also 
in the adolescent population36.
Therefore, based on all of the above-mentioned evidence, we are prompted to formulate the hypothesis that 
the E167K variant is associated with circulating levels of aminotransferases as an indirect consequence of liver 
metabolic perturbations in the context of MetS and NAFLD, but not necessarily with liver injury or necrosis. 
Consequently, in population-based studies on NAFLD or MetS that do not include patients with liver biopsy, 
associations between the E167K variant and plasma levels of aminotransferases should not be regarded as surro-
gates of liver damage, but rather a derived-phenotype associated with liver fat overload.
The accumulation of supporting experimental evidence on the functional role of the E167K variant and 
TM6SF2 gene and protein strengthen our hypothesis. For instance, previous studies on the biological function 
of TM6SF2, either in vitro37 or in vivo by knockdown of Tm6sf2 in mice12,38, consistently demonstrated a critical 
role in lipoprotein metabolism, specifically in the secretion of very-low-density lipoproteins. The allelic-specific 
expression analysis of cDNA isolated from the liver tissue of patients with NAFLD confirmed that the expression 
levels of rs58542926-T allele are about 56% of that of the C allele24; also, patients with NAFLD have a reduced 
TM6SF2 protein expression in the liver24. Remarkably, a recent experimental work that used novel, genetically 
engineered, transgenic mouse models, such as mice that express TM6SF2 in the liver specifically, and also mice 
with CRISPR/Cas9-mediated knockout of Tm6sf2, showed that TM6SF2 did not alter either ALT or AST levels38. 
In addition, feeding with a high fat diet for 10–12 weeks did not induce either inflammation or the development 
of significant liver fibrosis38; furthermore, liver expression of tumor necrosis factor α and monocyte chemoat-
tractant protein-1 were neither induced in TM6SF2 KO mice38.
Finally, the current evidence on human studies suggest that the E167K variant exerts a modest effect on liver 
fat accumulation, as the carriers of the K-risk allele have a ~2.13-fold higher risk of developing NAFLD, and also 
show an approximately ~2.2–4% (depending on the inheritance-model) higher hepatic fat content when com-
pared with carriers of the EE genotype14. It is reasonable to then speculate that this modest effect on the risk of 
NAFLD is consequently associated with a modest effect on the disease severity, and specifically on liver damage 
and inflammation; unfortunately, a large proportion of studies included in this meta-analysis lack genotypes 
counts according to liver biopsy inflammatory scores, thereby precluding any further analysis. By contrast, the 
Figure 1. Association analysis on plasma level of ALT in patients with NAFLD: forest plot of rs58542926 
variant (homozygous EE vs. EK + KK) and random and fixed effect models. The effect indicates the 
standardized mean difference, the standard error and the corresponding lower and upper limits, and sample size 
of each study according to the dominant model of inheritance. Studies were ordered by sample size. The first 
author of the study and the year of publication are shown after the study name; Dongiovanni, 2015 HB: stands 
for hospital-based study on NAFLD; Dongiovanni, 2015b: SOS Study (Swedish Obese Subjects); Kozlitina, 
2014a: Dallas Heart Study; Kozlitina, 2014b: Dallas Biobank; Kozlitina, 2014c: Danish population Copenhagen 
Study; Goffredo 2015a: Caucasians, Goffredo 2015b: African Americans and Goffredo 2015c: Hispanics. Popul: 
indicates design features, GP: general population, HB: hospital-based, MO: morbid obese subjects. In the graph, 
the filled squares stand for the effect of individual studies, and filled diamonds express combined fixed and 
random effects.
www.nature.com/scientificreports/
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G-risk allele of PNPLA3-rs738409 that is associated with a 3.26-fold risk of developing NAFLD11 is associated 
with a 3.24-fold higher risk of higher necroinflammatory scores when compared with homozygous subjects for 
the C allele11. In conclusion, it is plausible to suggest that the association of rs58542926 with aminotransferase 
levels might be regarded as an epiphenomenon of the liver metabolic perturbations observed in NAFLD rather 
than a direct influence of the variant on liver damage or inflammation.
Material and Methods
Data Sources and Study Selection. Electronic searches of Pubmed at the National Library of Medicine 
(http://ncbi.nlm.nih.gov/entrez/query), Google Scholar and EMBASE and the Science Citation Index databases 
were performed using the search terms “TM6SF2” in all fields, and “rs58542926, gene or variants or polymor-
phism or alleles”. In addition, citations in retrieved articles as well as articles disclosed by the PubMed “related 
articles” link were further evaluated for inclusiveness. All the published evidence until March 2016 without any 
country restriction was included in the initial assessment; 48 studies were selected for the analysis.
The search and the assessment of the eligibility criteria was conducted by the authors (SS and CJP), who inde-
pendently performed this task; there were no discrepancies in this process and the inter-observer variability by 
calculating the kappa statistic was 1.0. A detailed description of the process of data collection, including identifi-
cation, screening, eligibility and selection of the studies can be found in the Supplementary Fig. 1.
This meta-analysis followed the appropriate methods for conducting the meta-analysis of genetic association 
studies, as stipulated in The Human Genome Epidemiology Network (HuGENet) guidelines (http://www.cdc.
gov/genomics/hugenet/participate.htm), which are specific for the assessment of the strength of evidence for 
gene-phenotype associations.
Inclusion and Exclusion Criteria for Data Source Selection. The protocol that includes the eligi-
bility criteria for selecting studies in our meta-analysis is as follows: candidate gene association studies, either 
population-based or hospital-based case-control, and GWAS concerning the TM6SF2 rs58542926, in which 
information on ALT and AST values as well as the number of subjects in each genotype was given, sufficient data 
to calculate outcomes was available, and genotyping was performed using a validated molecular method. As the 
literature search showed reports of the rs58542926 variant in NAFLD and viral hepatitis, a separate analysis for 
each main phenotype was conducted.
The exclusion criteria were as follows: duplicate publications, redundant information on genotyped subjects 
included in more than one study, and unpublished papers. Because the number of homozygous subjects for the 
T allele is either null in candidate association studies or small in the larger GWAS, we decided to compare the 
Figure 2. Association analysis on plasma level of AST in patients with NAFLD: forest plot of rs58542926 
variant (homozygous EE vs. EK + KK) and random and fixed effect models. The effect indicates the 
standardized mean difference, the standard error and the corresponding lower and upper limits, and sample size 
of each study according to the dominant model of inheritance. Studies were ordered by sample size. The first 
author of the study and the year of publication are shown after the study name; Dongiovanni, 2015 HB: stands 
for hospital-based study on NAFLD; Dongiovanni, 2015b: SOS Study (Swedish Obese Subjects); Kozlitina, 
2014a: Dallas Heart Study; Kozlitina, 2014b: Dallas Biobank; Kozlitina, 2014c: Danish population Copenhagen 
Study; Goffredo 2015a: Caucasians, Goffredo 2015b: African Americans and Goffredo 2015c: Hispanics. Popul: 
indicates design features, GP: general population, HB: hospital-based, MO: morbid obese subjects. In the graph, 
the filled squares stand for the effect of individual studies, and filled diamonds express combined fixed and 
random effects.
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homozygous for the C (Glu167) allele (EE genotype) vs. the carriers of the T allele (Lys167), specifically the hete-
rozygous EK+ homozygous KK genotypes, as explained earlier14. For each phenotype, we evaluated the associa-
tion results stratified by age and ethnicity.
Data Collection. From each study included in our meta-analysis, we retrieved relevant information on 
demographics, such as age, sex, and ethnicity, and circulating levels of ALT and AST expressed in international 
units (IU/L) and measured by any standard analytical method (variables expressed as mean ± standard deviation, 
SD); standard error and interquartile rank were converted to SD. Data on the explored phenotypes was extracted 
for the EE and EK+ KK genotypes, and the analyses were based on comparing the genotype groups without any 
further adjustment for confounding factors.
Statistical Analysis. While the main outcome (ALT and AST levels) was measured in IU/L across all studies, 
the expression of data was not always uniform, and potential variability across different laboratories could also 
be expected. Then, we attempted to homogenize the results through the use of standardized mean difference (D), 
which is the difference in means pertaining to cases and controls divided by the common within-group SD. The 
difference in means was used to estimate the magnitude of the absolute effect in IU/L. The statistical protocol 
applied to this study was already published in our previous work on the meta-analysis of the role of rs58542926 
on lipid traits and NAFLD14. While both the fixed and random effect models were assessed for all the explored 
variables, the random model was used to summarize statistical synthesis, as it assumes that the treatment effect is 
not the same across all of the studies. Thus, the goal was to estimate the average effect in the studies39, assuming 
that ethnicity or age may provide an important source of variability. Heterogeneity was evaluated with the Q 
statistic and I2 statistic, which is a transformation of Q that estimates the proportion of the variation in effect sizes 
Figure 3. Association analysis on plasma level of ALT (panel A) and AST (panel B) in patients with chronic 
hepatitis (B,C): forest plot of rs58542926 variant (homozygous EE vs. EK + KK) and random and fixed effect 
models. The effect indicates the standardized mean difference, the standard error and the corresponding lower 
and upper limits, and sample size of each study according to the dominant model of inheritance. Studies were 
ordered by sample size. The first author of the study and the year of publication are shown after the study name. 
Eslam 2016a: NAFLD, Eslam 2016b: chronic hepatitis (C), Eslam 2016c: chronic hepatitis (B). HB: hospital-
based. In the graph, the filled squares stand for the effect of individual studies, and filled diamonds express 
combined fixed and random effects.
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that is due to heterogeneity between the studies. In such cases, an I2 value of 0% indicated no observed heteroge-
neity, while greater values corresponded to increasing heterogeneity. In the case of heterogeneity, we identified 
study characteristics that stratified the studies into subsets with homogeneous effects. We considered the possible 
sources of heterogeneity and stratified the studies by age and ethnicity, and also repeated the analysis separately 
for each group. If the association became homogeneous after stratification or after excluding the outlier studies, 
we recalculated the overall effect and 95% CI, and no further action was taken. Although the studies excluded in 
this way cannot be considered outliers, excluding studies that contribute the most to heterogeneity is an unbiased 
way of achieving the homogeneity required for a stringent meta-analysis39. To check for publication bias, we used 
a visual inspection of funnel plots and Begg and Mazumdar’s rank correlation test (this test, which is also known 
as rank correlation coefficient or simply Kendall’s τ au, reports the rank correlation between the standardized 
effect size and the variances, or standard errors, of these effects)40. A p value of ≤ 0.05 was considered statistically 
significant. All calculations were performed using the Comprehensive Meta-Analysis computer program (Biostat, 
Englewood, NJ, USA).
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